Imaging plays a vital role in the management of non-small cell lung cancer including diagnosis, staging and follow-up. CT and magnetic resonance imaging (MRI) are used in staging and provide anatomical information but have well known limitations in differentiating reactive from malignant nodes, and fibrosis from active disease and in defining the extent of invasion. MRI with its superior soft tissue contrast provides optimal information on brachial plexus and central nervous system involvement. Functional imaging using 2-18 fluoro-deoxyglucose positron emission tomography is increasingly being used to provide unique information and when combined with anatomic imaging will provide better staging information for both local disease and the extent of metastases.

Author

S C Rankin

Contact Details

Corresponding address:
Guy’s and St.Thomas NHS Trust,
Guy’s Hospital,
St.Thomas Street,
London, UK

Reference

ICIS Cancer Imaging volume 4
DOI: 10.1102/1470-7330.2004.0013

Date Posted

14 February 2004

Print PDF

Size

33.40 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	1 second
ADSL 512Kb/s (Broadband):	1 second
64 Kb/s (ISDN):	4 seconds
33.3 Kb/s (Typical Modem):	8 seconds

Screen PDF

Size

166.59 KB

Minimum Estimated Download Times

ADSL 2Mb/s (Broadband):	1 second
ADSL 512Kb/s (Broadband):	2 seconds
64 Kb/s (ISDN):	20 seconds
33.3 Kb/s (Typical Modem):	40 seconds

No part of this publication or site may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, e-MED Limited, Permissions, PO Box 61053, London, SE16 7YZ. Tel: +44 (0)207 719 8989 Fax: +44 (0)560 126 4446, permissions@cancerimaging.org.